摘要
目的:观察温阳中药复方肝之福在实验性肝纤维化形成过程中的防治作用,并探讨其疗效机制. 方法:Wistar大鼠45只随机分为4组:正常对照组、肝之福组、秋水仙碱组及模型对照组.除正常组外,其余3组均采用CCl4SC及饮用100 mL/L乙醇的方法制备大鼠肝纤维化模型.在造模的同时,肝之福组予肝之福灌胃,秋水仙碱组予秋水仙碱灌胃,模型对照组则予等量生理盐水灌胃,1次/d,共30 d.实验结束后分别采血测定肝功能、肝纤维化指标,取肝组织测定羟脯氨酸(Hyp)含量、丙二醛(MDA)含量、超氧化物歧化酶(SOD)活性,并根据炎症活动度及纤维化半定量计分系统(SSS)评分,以观察预防用药组与模型对照组的组织学变化,同时对肝组织内Ⅰ、Ⅲ、Ⅳ型胶原进行染色并定量分析. 结果:与模型对照组相比,肝之福组的肝功能明显改善, 肝纤维化指标显著降低,Hyp含量由1.52±0.35 mg/g 减少到1.12±0.29 mg/g(P<0.05),MDA含量由16.3±6.0 gmol/g减少到8.8±2.1 gmol/g(P<0.01),而SOD活性则由86.33±17.74 nkat/g升高至122.01±19.12 nkat/g (P<0.01);同时,SSS评分炎症活动度及肝纤维化程度明显改善,肝组织内Ⅰ型、Ⅲ型、Ⅳ型胶原含量下降.经比较,肝之福抗肝纤维化的上述疗效与秋水仙碱相当. 结论:肝之福可保护肝脏,预防或缓解肝纤维化的形成,抗脂质过氧化是其可能的作用机制.
AIM: To investigate the effect of compound Ganzhifu on experimental hepatic fibrosis and its possible mechanism. METHODS: Forty-five Wistar rats were randomly divided into four groups: normal (N) group, Ganzhifu (G) group, colchicine (C) group and model (M) group.AII the rats, except those in N group, were given CCI4 by subcutaneous injection and alcohol (10%) by oral administration to establish the model of hepatic fibrosis. At the same time, the rats in G, C or M group were treated through stomach irrigation with Ganzhifu, colchicine or saline, respectively. Blood was collected for the examination of liver function and serum fibrosis markers. Hydroxyproline (Hyp), malondial dehyde (MDA) content, and superoxide disumutase (SOD) activity were determined in liver tissues. HE, Masson and Gorden-Sweet staining were used to examine the pathological changes in liver tissue sections. Inflammation and fibrosis were evaluated by semi-quantitative scoring system (SSS). In addition, The expression of typel, III, IV collagens was detected by immunohistochemistry. RESULTS: Compared with that in M group, liver function was improved remarkably in G group, and there were significant decreases in the liver fibrosis markers (Hyp: 1.52±0.35 mg/g vs 1.12±0.29 mg/g, P<0.05; MDA: 16.3±6.0μmol/g vs8.8±2.1μmol/g, P<0.01). However, the SOD activity was notably elevated (86.33±17.74 nkal/g vs 122.01 ±19.12 nkat/g, P<0.01).Less inflammation, lower degree of fibrosis and reduced content of typel, III, IV collagens were observed in G group than in M group. No significant difference was found between the effects of Ganzhifuand colchi-cines against fibrosis. CONCLUSION: Ganzhifucan protect liver from fibrosis and the mechanism may be related to its anti-oxidative effect.
出处
《世界华人消化杂志》
CAS
北大核心
2005年第3期330-335,共6页
World Chinese Journal of Digestology
基金
四川省卫生所科研基金资助项目
No.F0196~~
关键词
温阳中药
复方肝之福
大鼠
肝纤维化
防治
Compound Ganzhifu
Hepatic fibrosis
Immunohistochemistry
Inflammation
Semi-quantative scoring system
